Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kathryn B, Alguire"'
Autor:
Daniel Haggstrom, Pam K. Mangat, Susan Halabi, Ramya Thota, Anu G. Gaba, Kathryn B. Alguire, Elie G. Dib, Samiha Islam, Andrew L. Rygiel, Richard L. Schilsky, Elizabeth Garrett-Mayer, Eugene R Ahn, Kaitlyn R. Antonelli, Ashish Sangal, Pamela A. Crilley, Alissa S. Marr, Suanna S. Bruinooge, Carmen Julia Calfa, Timothy L. Cannon
Publikováno v:
JCO Precision Oncology. :757-766
PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known t
Autor:
Eugene R, Ahn, Pam K, Mangat, Elizabeth, Garrett-Mayer, Susan, Halabi, Elie G, Dib, Daniel E, Haggstrom, Kathryn B, Alguire, Carmen J, Calfa, Timothy L, Cannon, Pamela A, Crilley, Anu G, Gaba, Alissa S, Marr, Ashish, Sangal, Ramya, Thota, Kaitlyn R, Antonelli, Samiha, Islam, Andrew L, Rygiel, Suanna S, Bruinooge, Richard L, Schilsky
Publikováno v:
JCO precision oncology. 4
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer with genomic alterations known to be dru
Autor:
Eugene R Ahn, Anu G. Gaba, Suanna S. Bruinooge, Richard L. Schilsky, Ricardo H. Alvarez, Carmen Julia Calfa, Kaitlyn R. Antonelli, Elizabeth Garrett-Mayer, Samiha Islam, Elie G. Dib, Andrew L. Rygiel, Timothy L. Cannon, Alissa S. Marr, Ramya Thota, Kathryn B. Alguire, Susan Halabi, Daniel Haggstrom, Pamela A. Crilley, Ashish Sangal, Pam K. Mangat
Publikováno v:
Journal of Clinical Oncology. 37:9041-9041
9041 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of NSCLC pts with CDKN2A loss or mutation treated wi
Autor:
Douglas Flora, Peter Ruehlman, David M. Waterhouse, Cassie M. Lane, Michael McCleod, Kent C. Shih, Evan Z. Lang, Kathryn B. Alguire, Johanna C. Bendell, N. W. Peacock, Chris Earwood, Ahmed Zakari
Publikováno v:
Cancer investigation. 34(5)
Purpose: To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors.Methods: Patients received bevacizumab 15 mg/kg and pertuzumab 420 mg IV q21 days with octreotide depot 30 mg IM q28 days.Res
Autor:
Michael McCleod, Chris Earwood, Johanna C. Bendell, N. W. Peacock, Irfan Firdaus, Kent C. Shih, Kathryn B. Alguire, Ahmed Zakari, Evan Z. Lang, Peter Ruehlman, Douglas Flora
Publikováno v:
Journal of Clinical Oncology. 30:4127-4127
4127 Background: Targeted agents are used to treat well-differentiated NET. Octreotide binds somatostatin receptors and improves time to progression (TTP) of carcinoid tumors, and VEGF pathway targeting improves TTP of pancreatic NET. HER2 overexpres